China Sinopharm chief rules out high price for coronavirus vaccine
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Tuesday
August 09, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
TUESDAY, AUGUST 09, 2022
China Sinopharm chief rules out high price for coronavirus vaccine

Coronavirus chronicle

Reuters
18 August, 2020, 06:25 pm
Last modified: 18 August, 2020, 06:26 pm

Related News

  • Children aged 5-11 to get Covid jabs from 11 August
  • Some Omicron sub-variants escaping antibodies from Sinopharm shot
  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says

China Sinopharm chief rules out high price for coronavirus vaccine

Sinopharm has said its experimental vaccine could be ready for public use by the end of this year. It has entered a late-stage human test in the United Arab Emirates to gather proof of efficacy for final regulatory approvals

Reuters
18 August, 2020, 06:25 pm
Last modified: 18 August, 2020, 06:26 pm
FILE PHOTO: The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong, China March 29, 2016. REUTERS/Bobby Yip/File Photo
FILE PHOTO: The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong, China March 29, 2016. REUTERS/Bobby Yip/File Photo

A potential coronavirus vaccine being developed by a unit of China National Pharmaceutical Group (Sinopharm) could cost no more than 1,000 yuan ($144.27) for two shots, state media on Tuesday quoted chairman Liu Jingzhen as saying.

Sinopharm has said its experimental vaccine could be ready for public use by the end of this year. It has entered a late-stage human test in the United Arab Emirates to gather proof of efficacy for final regulatory approvals.

"It will not be priced very high. It is expected to cost a few hundred yuan for a shot, and for two shots it should be less than 1,000 yuan," Liu told the Guangming Daily newspaper.

Governments and drugmakers around the world are in a frenetic race to develop a Covid-19 vaccine. More than 200 candidates are in development, including more than 20 in human clinical trials.

Moderna Inc said earlier this month that smaller volumes of its experimental vaccine have been priced at $32-$37 per dose.

Last month, the US government struck a deal for an experimental vaccine being developed by Pfizer and partner BioNTech SE that secures enough to innoculate 50 million Americans for about $40 a person.

Sinopharm's Liu did not mention whether China's state-backed nationwide insurance program would cover some of the vaccine costs for consumers, or whether it could be included in the country's free vaccination scheme.

China National Biotec Group (CNBG), a Sinopharm unit, has moved two vaccine strains using the same method into human trials. Its plants in Wuhan and Beijing combined could make over 200 million doses of the drug annually.

($1 = 6.9316 Chinese yuan renminbi)

Sinopharm / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Anwar Group looks beyond slowdown – invests Tk5,000cr
    Anwar Group looks beyond slowdown – invests Tk5,000cr
  • A unique exchange rate regime
    A unique exchange rate regime
  • File Photo of Bangladesh Bank : Salahuddin Ahmed/TBS
    Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 

MOST VIEWED

  • Workers wearing protective suits arrive to a building under lockdown for compulsory testing, following the coronavirus disease (COVID-19) outbreak in Hong Kong, China January 7, 2022. Photo :Reuters
    Hong Kong cuts Covid quarantine stay for incoming travellers
  • People line up for nucleic acid tests during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    China's Sanya holiday hotspot shuts duty-free malls, venues to curb Covid
  • FILE PHOTO: People wearing protective face masks walk amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea May 15, 2020, in this photo released by Kyodo. Mandatory credit Kyodo/via REUTERS
    North Korea marks end of first Covid wave, but risks persist
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    South Africa reports first death causally linked to Covid vaccine
  • 'Living with Covid': Where the pandemic could go next
    'Living with Covid': Where the pandemic could go next
  • A worker, wearing a protective suit following the coronavirus disease (COVID-19) outbreak, transports luggage on the tarmac of Wuhan Tianhe International Airport, on a hot summer day in Wuhan, Hubei province, China July 14, 2022. cnsphoto via REUTERS
    China's Wuhan locks down 1m residents amid new Covid cases

Related News

  • Children aged 5-11 to get Covid jabs from 11 August
  • Some Omicron sub-variants escaping antibodies from Sinopharm shot
  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says

Features

Photo: BSS

Begum Fazilatunnessa Mujib . . . woman of moral power

13h | Thoughts
Will Glass Cosmetics be your next skincare holy grail?

Will Glass Cosmetics be your next skincare holy grail?

17h | Brands
Akij Tableware: More than just dishes on a table

Akij Tableware: More than just dishes on a table

17h | Brands
Deeply depressed and afraid of living in total darkness, the Noakhali-based housewife Rasheda desires nothing but to get her vision back. Photo: Noor-A-Alam

Blind people need 25,000 corneas. Sandhani gets around 25

18h | Panorama

More Videos from TBS

What caused the Megalodon to go extinct?

What caused the Megalodon to go extinct?

9h | Videos
92nd birth anniversary of Bangamata Fazilatunnesa Mujib today

92nd birth anniversary of Bangamata Fazilatunnesa Mujib today

10h | Videos
Challenges the world will face after 10 years

Challenges the world will face after 10 years

12h | Videos
Ukraine-Russia war at new stage, fear of nuclear radiation increasing

Ukraine-Russia war at new stage, fear of nuclear radiation increasing

13h | Videos

Most Read

1
Diesel price hiked by Tk34 per litre, Octane by Tk46
Energy

Diesel price hiked by Tk34 per litre, Octane by Tk46

2
Housing projects sprouting up by Dhaka-Mawa expressway
Real Estate

Housing projects sprouting up by Dhaka-Mawa expressway

3
Infographic: TBS
Banking

Dollar rate will be left to market after two months: Governor

4
Bangladesh to resume talks for Ukrainian wheat import
Economy

Bangladesh to resume talks for Ukrainian wheat import

5
A liquefied natural gas (LNG) tanker is tugged towards a thermal power station in Futtsu, east of Tokyo, Japan November 13, 2017. REUTERS/Issei Kato/File Photo
Energy

Summit proposes long-term LNG supply to Petrobangla

6
Dollar for LC settlement reaches new high at Tk110
Banking

Dollar for LC settlement reaches new high at Tk110

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net